secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001193125-26-202610
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna Therapeutics appoints Nadia Dac as CCO; leads commercial launch for miv-cel in stiff person syndrome
--------------------------------------------------------------------------------

- Nadia Dac appointed Chief Commercial Officer effective May 4, 2026; has 30+ years experience in neurology and rare disease launches.
- She will lead commercial strategy for miv-cel (KYV-101), which is poised for first approval in stiff person syndrome with neuroimmunology expansion.
- Previously CCO at Omeros (launched Yartemlea) and Alder (launched Vyepti); held leadership roles at AbbVie, Novartis, Biogen.
- Received inducement option for 300,000 shares vesting over 4 years (25% after 1 year, monthly thereafter); exercise at May 4 closing price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526202610/0001193125-26-202610-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526202610/kytx-20260415.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-202610

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer